BR112012012903A2 - compostos de espiropiperidina - Google Patents
compostos de espiropiperidinaInfo
- Publication number
- BR112012012903A2 BR112012012903A2 BR112012012903A BR112012012903A BR112012012903A2 BR 112012012903 A2 BR112012012903 A2 BR 112012012903A2 BR 112012012903 A BR112012012903 A BR 112012012903A BR 112012012903 A BR112012012903 A BR 112012012903A BR 112012012903 A2 BR112012012903 A2 BR 112012012903A2
- Authority
- BR
- Brazil
- Prior art keywords
- spiropiperidine compounds
- spiropiperidine
- compounds
- compound
- formula
- Prior art date
Links
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26518109P | 2009-11-30 | 2009-11-30 | |
| PCT/US2010/057359 WO2011066183A1 (en) | 2009-11-30 | 2010-11-19 | Novel spiropiperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012012903A2 true BR112012012903A2 (pt) | 2017-03-01 |
Family
ID=43384775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012012903A BR112012012903A2 (pt) | 2009-11-30 | 2010-11-19 | compostos de espiropiperidina |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8822486B2 (https=) |
| EP (1) | EP2507228B1 (https=) |
| JP (1) | JP5709889B2 (https=) |
| KR (1) | KR101410103B1 (https=) |
| CN (1) | CN102648195B (https=) |
| AR (1) | AR078948A1 (https=) |
| AU (1) | AU2010324987B2 (https=) |
| BR (1) | BR112012012903A2 (https=) |
| CA (1) | CA2781292C (https=) |
| CL (1) | CL2012001321A1 (https=) |
| CR (1) | CR20120296A (https=) |
| DO (1) | DOP2012000139A (https=) |
| EA (1) | EA020507B1 (https=) |
| EC (1) | ECSP12011930A (https=) |
| ES (1) | ES2526568T3 (https=) |
| GT (1) | GT201200164A (https=) |
| IL (1) | IL219594A0 (https=) |
| MA (1) | MA33840B1 (https=) |
| MX (1) | MX2012006233A (https=) |
| NZ (1) | NZ600203A (https=) |
| PE (1) | PE20121474A1 (https=) |
| PH (1) | PH12012501052A1 (https=) |
| TN (1) | TN2012000248A1 (https=) |
| TW (1) | TW201141866A (https=) |
| WO (1) | WO2011066183A1 (https=) |
| ZA (1) | ZA201203055B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| CN104710381A (zh) | 2009-12-25 | 2015-06-17 | 持田制药株式会社 | 新的3-羟基-5-芳基异噻唑衍生物 |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| RU2013152631A (ru) | 2011-04-27 | 2015-06-10 | Мотида Фармасьютикал Ко., Лтд. | Новое 3-гидроксиизотиазол-1-окидное производное |
| JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
| EP2970161B8 (en) * | 2013-03-14 | 2018-10-17 | Janssen Pharmaceutica NV | Gpr120 agonists for the treatment of type ii diabetes |
| EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN110590767B (zh) * | 2019-08-29 | 2021-10-08 | 南方科技大学 | 一种合成amg837的方法 |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| CN1768041A (zh) * | 2003-04-04 | 2006-05-03 | 麦克公司 | 作为黑皮质素－4受体激动剂的酰化螺哌啶衍生物 |
| US7504506B2 (en) | 2003-11-04 | 2009-03-17 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CA2558585C (en) | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US7517910B2 (en) * | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| EP1795527B1 (en) * | 2004-09-07 | 2009-04-22 | Banyu Pharmaceutical Co., Ltd. | Carbamoyl-substituted spiro derivative |
| CA2657639A1 (en) * | 2006-07-19 | 2008-01-24 | Astrazeneca Ab | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
| US20090247560A1 (en) * | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| ATE486877T1 (de) * | 2006-12-29 | 2010-11-15 | Hoffmann La Roche | Azaspiroderivate |
| AU2008241490B2 (en) * | 2007-04-16 | 2011-07-21 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators |
| BRPI0818687A2 (pt) * | 2007-10-26 | 2017-05-02 | Japan Tobacco Inc | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
-
2010
- 2010-11-08 AR ARP100104151A patent/AR078948A1/es not_active Application Discontinuation
- 2010-11-10 TW TW099138725A patent/TW201141866A/zh unknown
- 2010-11-19 PH PH1/2012/501052A patent/PH12012501052A1/en unknown
- 2010-11-19 CN CN201080054116.3A patent/CN102648195B/zh not_active Expired - Fee Related
- 2010-11-19 ES ES10784390.6T patent/ES2526568T3/es active Active
- 2010-11-19 JP JP2012542076A patent/JP5709889B2/ja not_active Expired - Fee Related
- 2010-11-19 AU AU2010324987A patent/AU2010324987B2/en not_active Ceased
- 2010-11-19 WO PCT/US2010/057359 patent/WO2011066183A1/en not_active Ceased
- 2010-11-19 MX MX2012006233A patent/MX2012006233A/es not_active Application Discontinuation
- 2010-11-19 BR BR112012012903A patent/BR112012012903A2/pt not_active IP Right Cessation
- 2010-11-19 US US13/505,470 patent/US8822486B2/en not_active Expired - Fee Related
- 2010-11-19 EP EP10784390.6A patent/EP2507228B1/en active Active
- 2010-11-19 NZ NZ600203A patent/NZ600203A/xx not_active IP Right Cessation
- 2010-11-19 KR KR1020127013788A patent/KR101410103B1/ko not_active Expired - Fee Related
- 2010-11-19 PE PE2012000730A patent/PE20121474A1/es not_active Application Discontinuation
- 2010-11-19 EA EA201290416A patent/EA020507B1/ru not_active IP Right Cessation
- 2010-11-19 CA CA2781292A patent/CA2781292C/en not_active Expired - Fee Related
-
2012
- 2012-04-25 ZA ZA2012/03055A patent/ZA201203055B/en unknown
- 2012-05-03 IL IL219594A patent/IL219594A0/en unknown
- 2012-05-15 DO DO2012000139A patent/DOP2012000139A/es unknown
- 2012-05-20 EC ECSP12011930 patent/ECSP12011930A/es unknown
- 2012-05-22 TN TNP2012000248A patent/TN2012000248A1/en unknown
- 2012-05-23 CL CL2012001321A patent/CL2012001321A1/es unknown
- 2012-05-28 GT GT201200164A patent/GT201200164A/es unknown
- 2012-05-30 CR CR20120296A patent/CR20120296A/es not_active Application Discontinuation
- 2012-06-21 MA MA34993A patent/MA33840B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201141866A (en) | 2011-12-01 |
| TN2012000248A1 (en) | 2013-12-12 |
| US8822486B2 (en) | 2014-09-02 |
| CL2012001321A1 (es) | 2013-11-15 |
| ECSP12011930A (es) | 2012-07-31 |
| ES2526568T3 (es) | 2015-01-13 |
| AU2010324987B2 (en) | 2014-01-30 |
| CN102648195A (zh) | 2012-08-22 |
| PE20121474A1 (es) | 2012-11-05 |
| PH12012501052A1 (en) | 2013-02-04 |
| EA201290416A1 (ru) | 2012-11-30 |
| KR101410103B1 (ko) | 2014-06-25 |
| US20120220616A1 (en) | 2012-08-30 |
| WO2011066183A1 (en) | 2011-06-03 |
| ZA201203055B (en) | 2013-09-25 |
| MX2012006233A (es) | 2012-07-03 |
| KR20120088770A (ko) | 2012-08-08 |
| IL219594A0 (en) | 2012-06-28 |
| JP5709889B2 (ja) | 2015-04-30 |
| GT201200164A (es) | 2014-02-27 |
| CA2781292A1 (en) | 2011-06-03 |
| DOP2012000139A (es) | 2012-08-15 |
| MA33840B1 (fr) | 2012-12-03 |
| EP2507228B1 (en) | 2014-11-05 |
| CA2781292C (en) | 2014-04-22 |
| EA020507B1 (ru) | 2014-11-28 |
| EP2507228A1 (en) | 2012-10-10 |
| CN102648195B (zh) | 2015-01-07 |
| AR078948A1 (es) | 2011-12-14 |
| NZ600203A (en) | 2013-09-27 |
| AU2010324987A1 (en) | 2012-07-26 |
| CR20120296A (es) | 2012-07-16 |
| JP2013512277A (ja) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012012903A2 (pt) | compostos de espiropiperidina | |
| BR112012008889A2 (pt) | compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes | |
| EP2415749A4 (en) | NOVEL SALVIANOLIC ACID COMPOUND L, PROCESS FOR THE PREPARATION AND USE | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112014027359A2 (pt) | moduladores da série de reação complementar e usos dos mesmos | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX2019003738A (es) | Compuestos antivirales. | |
| MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
| MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| EA201690521A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
| BR112014003079A2 (pt) | derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| UY31803A (es) | Compuesto cristalino | |
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| BR112012013918A2 (pt) | inibidores de diacil glicerol acil transferase | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| IN2014DN03010A (https=) | ||
| BR112014000485A2 (pt) | derivados de azetidina para o tratamento de transtornos relacionados à melanina | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| BR112013027982A2 (pt) | derivados de isoindolinona | |
| WO2014147578A3 (en) | Antibacterial compounds against drug resistant bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |